Table 2.
Effect estimates of compound Kushen injection for breast cancer.
| Outcomes and comparisons | Studies | Participants | Effect estimate (95%CI) REM | P value | Study ID references | |
|---|---|---|---|---|---|---|
| Compound Kushen injection plus chemotherapy versus chemotherapy alone | ||||||
| ORR | Stage II∼III | 7 | 656 | RR 1.31, [1.17, 1.46], I2 = 0% | P=0.002 | [28, 29, 42, 43, 46, 48, 50] |
| Stage IV | 6 | 533 | RR 1.33, [1.11, 1.60], I2 = 0% | P=0.002 | [36, 37, 39–41, 54] | |
|
| ||||||
| DCR | Stage II∼III | 7 | 656 | RR 1.20, [1.12, 1.28], I2 = 0% | P < 0.001 | [28, 29, 42, 43, 46, 48, 50] |
| Stage IV | 6 | 533 | RR 1.22, [1.11, 1.35], I2 = 0% | P < 0.001 | [36, 37, 39–41, 54] | |
|
| ||||||
| ORR | WHO criteria | 10 | 825 | RR 1.36, [1.18, 1.56], I2 = 2% | P < 0.001 | [30–32, 36, 39, 40, 42, 44, 48, 50] |
| RECIST criteria | 6 | 450 | RR 1.40, [1.16, 1.68], I2 = 0% | P < 0.001 | [34, 37, 46, 49, 53, 54] | |
|
| ||||||
| DCR | WHO criteria | 10 | 825 | RR 1.17, [1.08, 1.28], I2 = 30% | P < 0.001 | [30–32, 36, 39, 40, 42, 44, 48, 50] |
| RECIST criteria | 6 | 450 | RR 1.35, [1.21, 1.52], I2 = 0% | P < 0.001 | [34, 37, 46, 49, 53, 54] | |
|
| ||||||
| KPS score improvement rate | Stage II∼III | 5 | 468 | RR 2.93, [1.88, 4.56], I2 = 0% | P < 0.001 | [28, 38, 42, 47, 48] |
| Stage IV | 4 | 343 | RR 2.98, [1.88, 4.72], I2 = 0% | P < 0.001 | [36, 37, 40, 41] | |
|
| ||||||
| QoL-BREF score | 1 | 94 | MD 18.11, [16.50, 19.72] | P < 0.001 | [43] | |
| PFS | 1 | 94 | MD 2.24, [1.26, 3.22] | P < 0.001 | [43] | |
| OS | 1 | 94 | MD 2.24, [1.45, 3.43] | P < 0.001 | [43] | |
| ADRs | Leukocyte decrease | 15 | 1121 | RR 0.60, [0.5, 0.71], I2 = 40% | P < 0.001 | [27, 30–34, 36, 37, 39, 41, 42, 47, 48, 53, 54] |
| Platelet decrease | 9 | 750 | RR 0.41, [0.29, 0.58], I2 = 36% | P < 0.001 | [27, 28, 36, 37, 39, 42, 47, 53, 54] | |
| Liver injury | 13 | 1215 | RR 0.42, [0.31, 0.57], I2 = 26% | P < 0.001 | [26–28, 36, 37, 39, 42–44, 46, 50–52] | |
| Renal injury | 9 | 879 | RR 0.63, [0.46, 0.86], I2 = 0% | P=0.004 | [27, 28, 36, 37, 42, 46, 49–51] | |
| Nausea and vomiting | 14 | 1171 | RR 0.68, [0.59, 0.79], I2 = 43% | P < 0.001 | [26, 33, 34, 36, 37, 41, 43, 44, 46, 47, 49, 51, 53, 54] | |
| Diarrhea | 3 | 210 | RR 0.55, [0.35, 0.88], I2 = 0% | P < 0.001 | [26, 37, 49] | |
| Alopecia | 8 | 584 | RR 0.51, [0.39, 0.67], I2 = 32% | P < 0.001 | [27, 28, 33, 34, 36, 37, 49, 50, 53] | |
| Oral mucositis | 4 | 441 | RR 0.18, [0.07, 045], I2 = 0% | P < 0.001 | [26, 46, 50, 51] | |
| Tumor marker | Decrease rate of CEA | 3 | 336 | RR 1.19, [1.05, 1.35], I2 = 0% | P=0.007 | [25, 28, 52] |
| Decrease rate of CA153 | 2 | 206 | RR 1.15, [1.03, 1.27], I2 = 0% | P=0.009 | [25, 29] | |
Note: REM: random-effect models; CI: confidence intervals; MD: mean difference; RR: risk rate.